Alpha Cognition Inc
ACOG
Rang în acțiuni
#20056
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Preț acțiune
$8.63
Ultima sincronizare: 2026-10-21
Capitalizare de piață
$134.04M
Schimbare (1 zi)
0.23%
Schimbare (1 an)
71.57%
Țară
US
Tranzacționează Alpha Cognition Inc (ACOG)
Categorie
Healthcare
Istoric al prețului acțiunii pentru Alpha Cognition Inc (ACOG)
Cel mai mare preț de închidere: $5.46 pe 2024-12-01
Cel mai mic preț de închidere: $18.75 pe 2021-06-01
Cel mai mic preț de închidere: $18.75 pe 2021-06-01
Istoric al prețului acțiunii pentru Alpha Cognition Inc din 2021 până în 2026
Evoluția anuală a prețului acțiunii
| An | Performanță |
|---|---|
| 2024 | -51.49% |
| 2023 | 87.35% |
| 2022 | -73.46% |
| 2021 | 0.00% |
Prețul acțiunii pentru companii similare sau concurente
| Companie | Preț acțiune | Variație 1an% | Țara |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.05 | -4.32% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
